Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas

16 Aug 2018

Abstract excerpt

AIMS: The pyrosequencing (PSQ) has been regarded as the gold standard for MGMT promoter methylation testing in gliomas. However, various CpG combinations are currently used in clinical practice. We aimed to clarify how and how many CpGs combined is robust enough to predict MGMT mRNA expression and therapeutic prognosis of patients. METHODS: Total 223 patients with WHO III/IV gliomas were enrolled from Chinese...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30117294
DOI: 10.1111/cns.13040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomasPMID 30117294Read ↗

Comparative analysis of pyrosequencing and next-generation sequencing for assessing MGMT methylation in glioma patientsSemantic proximity Read ↗

A novel analytical model of MGMT methylation pyrosequencing offers improved predictive performance in patients with gliomasSemantic proximity Read ↗

Combining MGMT promoter pyrosequencing and protein expression to optimize prognosis stratification in glioblastomaSemantic proximity Read ↗

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCRSemantic proximity Read ↗

MGMT Pyrosequencing-Based Cut-Off Methylation Level and Clinical Outcome in Patients with Glioblastoma MultiformeSemantic proximity Read ↗

MGMT Promoter Methylation Correlates with an Overall Survival Benefit in Chinese High-Grade Glioblastoma Patients Treated with Radiotherapy and Alkylating Agent-Based Chemotherapy: A Single-Institution StudySemantic proximity Read ↗

Pyrosequencing Analysis of O-6-Methylguanine-DNA Methyltransferase Methylation at Different Cut-Offs of Positivity Associated with Treatment Response and Disease-Specific Survival in Isocitrate Dehydrogenase-Wildtype Grade 4 GlioblastomaSemantic proximity Read ↗

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?Semantic proximity Read ↗

Prognostic Role of Methylation Status of theMGMTPromoter Determined Quantitatively by Pyrosequencing in Glioblastoma PatientsSemantic proximity Read ↗

Clinical Neuropathology practice news 1-2014: Pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastomaSemantic proximity Read ↗

Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsSemantic proximity Read ↗

Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.